BioAdaptives (BioAdaptives) Debt-to-Equity

: -0.20 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

BioAdaptives's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.33 Mil. BioAdaptives's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. BioAdaptives's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-1.65 Mil. BioAdaptives's debt to equity for the quarter that ended in Dec. 2023 was -0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioAdaptives's Debt-to-Equity or its related term are showing as below:

BDPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.44 Med: -0.27 Max: 99999999.99
Current: -0.2

During the past 9 years, the highest Debt-to-Equity Ratio of BioAdaptives was 99999999.99. The lowest was -0.44. And the median was -0.27.

BDPT's Debt-to-Equity is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 0.41 vs BDPT: -0.20

BioAdaptives Debt-to-Equity Historical Data

The historical data trend for BioAdaptives's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives Annual Data

Trend

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.44

-0.35

-0.40

-0.27

-0.20

BioAdaptives Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																-0.27	-0.22	-0.23	-0.29	-0.20

Competitive Comparison

For the Packaged Foods subindustry, BioAdaptives's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioAdaptives Debt-to-Equity Distribution

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioAdaptives's Debt-to-Equity falls into.

BioAdaptives Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioAdaptives's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.329	+	0)	/	-1.647
	=	-0.20

BioAdaptives's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.329	+	0)	/	-1.647
	=	-0.20

BioAdaptives (OTCPK:BDPT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioAdaptives Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioAdaptives's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAdaptives (BioAdaptives) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128

Website

https://www.shopbioadaptives.com

BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.

Executives

Richard Chiang	other: Previous Officer and Director	460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling	director	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc.	10 percent owner	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling	director, officer: Pres, CEO, Secretary, CFO	2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128